Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

This summary covers recent developments in health, including the sentencing of Terren Peizer for insider trading, Novo Nordisk's drug trial results, new plans from health insurers on authorization ...

Investing.com - Morgan Stanley (NYSE: MS) has reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...